Candidate molecules as diagnostic biomarker for human uterine mesenchymal tumors
<p>Unfortunately, uterine leiomyosarcoma still has a poor prognosis. The National Cancer Institute reported that the median overall survival (mOS) at stage I to stage IV of leiomyosarcoma was 31 months. Norwegian reports show that mOS of uterine leiomyosarcoma is as poor as eight years at stag...
Tallennettuna:
| Päätekijät: | , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Kirja |
| Julkaistu: |
Annals of Cytology and Pathology - Peertechz Publications,
2020-05-14.
|
| Aiheet: | |
| Linkit: | Connect to this object online. |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|